Cyclacel Pharmaceuticals Inc (CYCC)
2.29
-0.05
(-2.14%)
USD |
NASDAQ |
May 17, 16:00
2.29
0.00 (0.00%)
After-Hours: 20:00
Cyclacel Pharmaceuticals Research and Development Expense (Annual): 19.16M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 19.16M |
| December 31, 2022 | 20.27M |
| December 31, 2021 | 14.93M |
| December 31, 2020 | 4.759M |
| December 31, 2019 | 4.658M |
| December 31, 2018 | 4.327M |
| December 31, 2017 | 4.237M |
| December 31, 2016 | 9.477M |
| December 31, 2015 | 12.38M |
| December 31, 2014 | 18.28M |
| December 31, 2013 | 11.28M |
| December 31, 2012 | 6.592M |
| Date | Value |
|---|---|
| December 31, 2011 | 9.206M |
| December 31, 2010 | 6.414M |
| December 31, 2009 | 9.766M |
| December 31, 2008 | 18.87M |
| December 31, 2007 | |
| December 31, 2006 | |
| December 31, 2005 | |
| December 31, 2004 | 19.70M |
| December 31, 2003 | 13.68M |
| December 31, 2002 | 14.66M |
| December 31, 2001 | 14.70M |
| December 31, 2000 | 11.26M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
4.658M
Minimum
2019
20.27M
Maximum
2022
12.75M
Average
14.93M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Corvus Pharmaceuticals Inc | 16.53M |
| Oragenics Inc | 15.49M |
| Relmada Therapeutics Inc | 54.81M |
| Alpine Immune Sciences Inc | 80.90M |
| MAIA Biotechnology Inc | 11.11M |